Informace o publikaci

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

Autoři	MORENO Carol MONTILLO Marco PANAYIOTIDIS Panayiotidis DIMOU Maria BLOOR Adrian DUPUIS Jehan SCHUH Anna NORIN Stefan GEISLER Christian HILLMEN Peter DOUBEK Michael TRNĚNÝ Marek OBRTLIKOVA Petra LAURENTI Luca STILGENBAUER Stephan SMOLEJ Lukas GHIA Paolo CYMBALISTA Florence JAEGER Ulrich STAMATOPOULOS Kostas STAVROYIANNI Niki CARRINGTON Patrick ZOUABI Hamadi LEBLOND Veronique GOMEZ-GARCIA Juan C. RUBIO Martin MARASCA Roberto MUSURACA Gerardo RIGACCI Luigi FARINA Lucia PAOLINI Rossella POSPÍŠILOVÁ Šárka KIMBY Eva BRADLEY Colm MONTSERRAT Emili
Rok publikování	2015
Druh	Článek v odborném periodiku
Časopis / Zdroj	Haematologica
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://www.haematologica.org/content/haematol/100/4/511.full.pdf
Doi	http://dx.doi.org/10.3324/haematol.2014.118158
Obor	Onkologie a hematologie
Klíčová slova	MONOCLONAL-ANTIBODIES; HUMAN CD20; FLUDARABINE; RITUXIMAB; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; ALEMTUZUMAB; THERAPY; CLL
Přiložené soubory	EL_1299427.pdf
Popis	We report the largest retrospective, phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic leukemia. Total number of patients was 103; median age was 65 years (range 39-85). Median number of prior lines of therapy was 4 (range 1-13), including, in most cases, rituximab-, fludarabine-and alemtuzumab-based regimens; 13 patients had been allografted. Of 113 adverse events, 28 (29%) were considered to be directly related to ofatumumab. Grade 3-4 toxicities included neutropenia (10%), thrombocytopenia (5%), anemia (3%), pneumonia (17%), and fever (3%). Two heavily pre-treated patients developed progressive multifocal leukoencephalopathy. On an intention-to-treat analysis, the overall response rate was 22% (3 complete response, 1 incomplete complete response). Median progression-free and overall survival times were 5 and 11 months, respectively. This study confirms in a daily-life setting the feasibility and acceptable toxicity of ofatumumab treatment in advanced chronic lymphocytic leukemia. The complete response rate, however, was low. Therefore, treatment with ofatumumab should be moved to earlier phases of the disease. Ideally, this should be done in combination with other agents, as recently approved for ofatumumab plus chlorambucil as front-line treatment for patients unfit for fludarabine.